Sector
PharmaceuticalsOpen
₹6.4Prev. Close
₹6.7Turnover(Lac.)
₹22.62Day's High
₹6.4Day's Low
₹6.452 Week's High
₹052 Week's Low
₹0Book Value
₹54.77Face Value
₹10Mkt Cap (₹ Cr.)
70.13P/E
0EPS
0Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
---|---|---|---|---|
Equity Capital | 31.66 | 13.89 | 13.89 | 7.58 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 376.21 | 295.58 | 335.91 | 126.81 |
Net Worth | 407.87 | 309.47 | 349.8 | 134.39 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
---|---|---|---|---|
Revenue | 421.05 | 520.75 | 479.96 | 320.25 |
yoy growth (%) | -19.14 | 8.49 | 49.86 | |
Raw materials | -349.9 | -386.87 | -353.2 | -232.69 |
As % of sales | 83.1 | 74.29 | 73.58 | 72.65 |
Employee costs | -5.62 | -6.72 | -5.64 | -4.62 |
Y/e 31 Mar( In .Cr) | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
---|---|---|---|---|
Profit before tax | 1.46 | 47.67 | 63.04 | 54.64 |
Depreciation | -20.44 | -20.22 | -15.66 | -2.58 |
Tax paid | -0.61 | -2.22 | -22.01 | -18.57 |
Working capital | -161.61 | 197.17 | 142.56 | |
Other operating items |
Y/e 31 Mar | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -19.14 | 8.49 | 49.86 | |
Op profit growth | -46.09 | 0.37 | 49.25 | |
EBIT growth | -50.75 | -1.96 | 34.97 | |
Net profit growth | 22.52 | -98.66 | 13.92 |
Particulars (Rupees in Crores.) | Mar-2014 | Mar-2013 | Mar-2012 |
---|---|---|---|
Gross Sales | 421.04 | 520.76 | 479.95 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 421.04 | 520.76 | 479.95 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 7.86 | 4.71 | 2.35 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,746.35 | 128.99 | 4,06,363.37 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,010.5 | 76.41 | 1,58,395.81 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,472.15 | 25.16 | 1,17,087.88 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,074.25 | 56.83 | 1,03,662.87 | 485 | 0.91 | 2,330 | 222.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,223.6 | 19.57 | 1,01,457.61 | 849.4 | 0.66 | 4,997.8 | 322.47 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non Executive Director
Rajendra Kamat
Director
Anjali Jadhav
Additional Director
Dinesh Surana
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Dr.Datsons Labs Ltd
Summary
Aanjaneya Lifecare Ltd is a vertically integrated pharmaceutical company with manufacturing and marketing capabilities in APIs (Active Pharmaceutical Ingredients) with focus on anti-malarial, and Finished Dosage Forms (FDFs) catering to various therapeutic segments. The company is presently manufacturing second generation anti malarial which are Quinine and its salts. They are an integrated manufacturer of herbal formulations and have introduced our brand LivChek and Prosils in the domestic market and recently in semi regulated export market.The company has launched brands such as Anjtil (diareahhea), Rankorex (cough syrup), Doktor Qure (pain management), Prosils (herbal lozenges), EsyHil (crack heel cream), Aanmycin (skin - anti fungal) under the branded generic segment in the domestic market. They have also launched these brands in the semi regulated markets like Kenya, Tanzania, Haiti, Egypt, Domnican Republic and Jamaica.Aanjaneya Lifecare Ltd was incorporated on January 3, 2006 as a private limited company with the name Anjaneya Biotech Pvt Ltd. In the year 2007, the company commenced their commercial production APIs of salts of quinine a second generation anti malarial. In March 8, 2007, the name of the company was changed from Anjaneya Biotech Pvt Ltd to Aanjaneya Biotech Pvt Ltd. In the year 2008, the company increased the manufacturing capacity from 200,000 kg per annum to 360,000 kg per annum. In the year 2009, the company further increased the manufacturing capacit
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.